Competition between two expensive drugs is expected in the field of Neuromyelitis Optica Spectrum Disorder Aggravate (NMOSD)

According to related industries, Roche's Enspryng (Satralizumab) is in the process of domestic approval, while Handok's Soliris (Eculizumab) recently added an indication for optic neuromyelitis.

Soliris has been used only as a treatment for paroxysmal nocturnal hemoglobinuria (PNH), but the indication has been expanded.

Enspryng is currently competing with Soliris in the United States, and is attracting attention because It is attracting attention because it is cheaper than Soliris. Alexion, developer of Soliris, added an indication for NMOSD in the U